Treprostinil Delivery System Cleared to Be Prefilled at Specialty Pharmacies
Remunity is indicated for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension in patients ≥22 years of age.
Pulmonary Hypertension
INOpulse Promising for Pulmonary Hypertension With Pulmonary Fibrosis
Positive topline data from the phase 2b study of INOpulse® delivery system announced for the treatment of pulmonary hypertension associated with pulmonary fibrosis.
Pulmonary Hypertension Risk Estimation Changes May Predict Mortality After Valve Replacement
Incorporating preoperative right heart measurements into the standard pulmonary hypertension risk estimation model may allow for better risk stratification following aortic valve replacement.
Pulmonary Hypertension With Left-Sided HF: Searching for Appropriate Treatment, Management
Pulmonary hypertension can be a severe and potentially debilitating complication in patients with chronic left-sided heart failure.
Anticoagulation Improves Outcomes in Idiopathic PAH, but Not CTD-PAH
Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
No Causal Association Between Red Cell Distribution Width and PAH
No causal association between elevated red cell distribution width and pulmonary arterial hypertension was established.
Drug Device Promising for Pulmonary Hypertension Associated With ILD
Bellerophon Therapeutics announced positive topline results from cohort 2 of a study of INOpulse delivery system for PH-ILD.
Factors Influencing Improved Survival in Systemic Sclerosis-Associated PAH
Pulmonary arterial hypertension with systemic sclerosis associated-survival improved over time among patients aged 70 years or younger, but not among the elderly.
Cardiac MRI Could Be Useful in Pulmonary Arterial Hypertension Risk Stratification
Cardiac magnetic resonance imaging is useful for risk stratification in patients with pulmonary arterial hypertension.
Expert Consensus Survey: Prostacyclin Pathway Agent Use in Pulmonary Arterial Hypertension
A new consensus survey of expert opinions was published regarding the use of oral prostacyclin pathway agents in patients with various forms of pulmonary arterial hypertension.
Next post in Pulmonary Hypertension
